TY - JOUR
T1 - Molecular profile in endometrial carcinoma
T2 - can we predict the lymph node status? A systematic review and meta-analysis
AU - Luzarraga Aznar, Ana
AU - Bebia, Vicente
AU - Gomez-Hidalgo, Natalia Rodriguez
AU - López-Gil, Carlos
AU - Miguez, Marta
AU - Colas, Eva
AU - Pérez-Benavente, Asunción
AU - Gil-Moreno, Antonio
AU - Cabrera, Silvia
N1 - © 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
PY - 2024/4/5
Y1 - 2024/4/5
N2 - Purpose: Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile. Methods: A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines. Results: Fifteen studies enrolling 3056 patients were included. Pooled prevalence LNM when considering only patients undergoing lymph node assessment was 4% for POLE-mutated (95%CI: 0-12%), 22% for no specific molecular profile (95% CI: 9-39%), 23% for Mismatch repair-deficiency (95%CI: 10-40%) and 31% for p53-abnormal (95%CI: 24-39%). Conclusions: The presence of LNM seems to be influenced by molecularclassification. P53-abnormal group presents the highest rate of nodal involvement, and POLE-mutated the lowest.
AB - Purpose: Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile. Methods: A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines. Results: Fifteen studies enrolling 3056 patients were included. Pooled prevalence LNM when considering only patients undergoing lymph node assessment was 4% for POLE-mutated (95%CI: 0-12%), 22% for no specific molecular profile (95% CI: 9-39%), 23% for Mismatch repair-deficiency (95%CI: 10-40%) and 31% for p53-abnormal (95%CI: 24-39%). Conclusions: The presence of LNM seems to be influenced by molecularclassification. P53-abnormal group presents the highest rate of nodal involvement, and POLE-mutated the lowest.
KW - Endometrial cancer
KW - Lymph node involvement
KW - Molecular classification
KW - Endometrial cancer
KW - Molecular classification
KW - Lymph node involvement
KW - Endometrial cancer
KW - Molecular classification
KW - Lymph node involvement
UR - http://www.scopus.com/inward/record.url?scp=85189316189&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/6a52cb6c-f8c2-3b88-86ce-04b8249aa388/
UR - https://portalrecerca.uab.cat/en/publications/8ba1a61d-1638-4558-97d2-d3cf1c18b8c1
U2 - 10.1007/s12094-024-03401-y
DO - 10.1007/s12094-024-03401-y
M3 - Article
C2 - 38578538
AN - SCOPUS:85189316189
SN - 1699-048X
VL - 26
SP - 1768
EP - 1778
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
IS - 7
ER -
